SVRA
Price:
$6.37
Market Cap:
$1.30B
Savara Inc., a clinical stage biopharmaceutical company, focuses on rare respiratory diseases. Its lead product candidate is molgramostim, an inhaled granulocyte-macrophage colony-stimulating factor, which is in Phase III development stage for the treatment of autoimmune pulmonary alveolar proteinosis. The company is headquartered in Austin, Texas.
Industry
Biotechnology
IPO Date
2017-04-28
Stock Exchange
NASDAQ
Ticker
SVRA
According to Savara Inc.’s latest financial reports and current stock price. The company's current ROE is -69.05%. This represents a change of 281.74% compared to the average of -18.09% of the last 4 quarters.
The mean historical ROE of Savara Inc. over the last ten years is -53.21%. The current -69.05% ROE has changed 29.76% with respect to the historical average. Over the past ten years (40 quarters), SVRA's ROE was at its highest in in the December 2016 quarter at 16.82%. The ROE was at its lowest in in the March 2017 quarter at -134.92%.
Average
-53.21%
Median
-47.45%
Minimum
-166.78%
Maximum
30.45%
Discovering the peaks and valleys of Savara Inc. ROE, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 240.85%
Maximum Annual ROE = 30.45%
Minimum Annual Increase = -182.03%
Minimum Annual ROE = -166.78%
| Year | ROE | Change |
|---|---|---|
| 2024 | -55.92% | 43.52% |
| 2023 | -38.97% | 10.08% |
| 2022 | -35.40% | 18.91% |
| 2021 | -29.77% | -61.37% |
| 2020 | -77.06% | 0.25% |
| 2019 | -76.87% | 35.23% |
| 2018 | -56.84% | 127.61% |
| 2017 | -24.97% | -182.03% |
| 2016 | 30.45% | -118.26% |
| 2015 | -166.78% | 240.85% |
The current ROE of Savara Inc. (SVRA) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages
3-year avg
-43.43%
5-year avg
-47.42%
10-year avg
-53.21%
Savara Inc.’s ROE is greater than Tyra Biosciences, Inc. (-31.80%), greater than Rezolute, Inc. (-62.82%), less than ProKidney Corp. (11.01%), greater than Kura Oncology, Inc. (-65.42%), less than Nanobiotix S.A. (155.77%), greater than EyePoint Pharmaceuticals, Inc. (-76.13%), greater than GH Research PLC (-16.71%), greater than Bicara Therapeutics Inc. Common Stock (-21.67%), greater than Geron Corporation (-30.28%), greater than Tango Therapeutics, Inc. (-79.72%),
| Company | ROE | Market cap |
|---|---|---|
| -31.80% | $1.18B | |
| -62.82% | $899.46M | |
| 11.01% | $723.22M | |
| -65.42% | $1.04B | |
| 155.77% | $1.04B | |
| -76.13% | $1.15B | |
| -16.71% | $952.15M | |
| -21.67% | $1.03B | |
| -30.28% | $810.71M | |
| -79.72% | $1.09B |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Savara Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like Savara Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the ROE?
How can you use the ROE?
What is Savara Inc.'s ROE?
How is the ROE calculated for Savara Inc. (SVRA)?
What is the highest ROE for Savara Inc. (SVRA)?
What is the 3-year average ROE for Savara Inc. (SVRA)?
What is the 5-year average ROE for Savara Inc. (SVRA)?
How does the current ROE for Savara Inc. (SVRA) compare to its historical average?